Low Stroke Risk in Children With Sickle Cell Disease in French Guiana: A Retrospective Cohort Study

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Jul 15

PMID 35836958

Authors

Julie Gargot

Marie-Claire Parriault

Antoine Adenis

Jerome Clouzeau

Kim-Anh Dinh Van

Balthazar Ntab

Antoine Defo

Mathieu Nacher

Narcisse Elenga

Affiliations

Soon will be listed here.

Abstract

One in every 227 babies born in French Guiana has sickle cell disease, which represents the greatest incidence in France. This study aimed to determine the incidence of stroke in children with sickle cell disease and its associated risk factors. This retrospective cohort study included all children with sickle cell disease diagnosed in the neonatal period who were born in French Guiana between 01/01/1992 and 12/31/2002. Of a total of 218 records, 122 patients were included. There were 70 HbSS/Sβ0 (58%), 40 HbSC (33%), and 11 Sβ + thalassemia (9%). The number of emergency admissions was significantly different between genotypes, with a higher number in SS/Sβ0 children ( = 0.004). There were significantly more acute chest syndromes ( = 0.006) and more elevated Lactate Dehydrogenase in SS/Sβ0 patients ( = 0.003). Three of these patients had ischemic strokes at a mean age of 6.9 years, and one had a hemorrhagic stroke at the age of 9,2 years. The incidence rate of ischemic stroke for SS/Sβ0 children was 3.1 (95% CI: 1.0-9.7) per 1,000 patient-years, and the clinically apparent stroke risk by the age of 15 years and 3 months was 6,4%. The incidence of hemorrhagic stroke was 1.1 (95% CI: 0.1-7.4) per 1,000 patients-years. No patient with SC or Sβ + thalassemia genotypes experienced any stroke.

References

Ware R, Davis B, Schultz W, Brown R, Aygun B, Sarnaik S . Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2015; 387(10019):661-670. PMC: 5724392. DOI: 10.1016/S0140-6736(15)01041-7. View

Makani J, Williams T, Marsh K . Sickle cell disease in Africa: burden and research priorities. Ann Trop Med Parasitol. 2007; 101(1):3-14. PMC: 5612390. DOI: 10.1179/136485907X154638. View

Hirtz D, Kirkham F . Sickle Cell Disease and Stroke. Pediatr Neurol. 2019; 95:34-41. DOI: 10.1016/j.pediatrneurol.2019.02.018. View

Wijdicks E, Sheth K, Carter B, Greer D, Kasner S, Kimberly W . Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(4):1222-38. DOI: 10.1161/01.str.0000441965.15164.d6. View

Hankins J, McCarville M, Rankine-Mullings A, Reid M, Lobo C, Moura P . Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. Am J Hematol. 2015; 90(12):1099-105. PMC: 4715740. DOI: 10.1002/ajh.24198. View

Brewin J, Kaya B, Chakravorty S . How I manage sickle cell patients with high transcranial doppler results. Br J Haematol. 2017; 179(3):377-388. DOI: 10.1111/bjh.14850. View

Simonnet C, Elanga N, Joly P, Vaz T, Nacher M . Genetic modulators of sickle cell disease in French Guiana: Markers of the slave trade. Am J Hum Biol. 2016; 28(6):811-816. DOI: 10.1002/ajhb.22871. View

DeBaun M, Gordon M, McKinstry R, Noetzel M, White D, Sarnaik S . Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014; 371(8):699-710. PMC: 4195437. DOI: 10.1056/NEJMoa1401731. View

Adams R, Brambilla D, Granger S, Gallagher D, Vichinsky E, Abboud M . Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood. 2004; 103(10):3689-94. DOI: 10.1182/blood-2003-08-2733. View

10.

Ohene-Frempong K, Weiner S, Sleeper L, Miller S, Embury S, MOOHR J . Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998; 91(1):288-94. View

11.

Connes P, Verlhac S, Bernaudin F . Advances in understanding the pathogenesis of cerebrovascular vasculopathy in sickle cell anaemia. Br J Haematol. 2013; 161(4):484-98. DOI: 10.1111/bjh.12300. View

12.

Adams R, McKie V, Brambilla D, Carl E, Gallagher D, Nichols F . Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998; 19(1):110-29. DOI: 10.1016/s0197-2456(97)00099-8. View

13.

Chevret S, Verlhac S, Ducros-Miralles E, Dalle J, Peffault de Latour R, De Montalembert M . Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by.... Contemp Clin Trials. 2017; 62:91-104. DOI: 10.1016/j.cct.2017.08.008. View

14.

Adams R, Brambilla D . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005; 353(26):2769-78. DOI: 10.1056/NEJMoa050460. View

15.

Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I . Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2010; 117(4):1130-40. DOI: 10.1182/blood-2010-06-293514. View

16.

Guilliams K, Fields M, Dowling M . Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease. Stroke. 2019; 50(2):266-273. PMC: 6385587. DOI: 10.1161/STROKEAHA.118.020482. View

17.

Abboud M, Yim E, Musallam K, Adams R . Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011; 118(4):894-8. PMC: 3148169. DOI: 10.1182/blood-2010-12-326298. View

18.

Lee M, Piomelli S, Granger S, Miller S, Harkness S, Brambilla D . Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood. 2006; 108(3):847-52. PMC: 1895848. DOI: 10.1182/blood-2005-10-009506. View

19.

Quinn C, McKinstry R, Dowling M, Ball W, Kraut M, Casella J . Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2012; 70(1):58-65. PMC: 3677221. DOI: 10.1001/jamaneurol.2013.576. View

20.

Knight-Madden J, Lee K, Elana G, Elenga N, Marcheco-Teruel B, Keshi N . Newborn Screening for Sickle Cell Disease in the Caribbean: An Update of the Present Situation and of the Disease Prevalence. Int J Neonatal Screen. 2020; 5(1):5. PMC: 7510201. DOI: 10.3390/ijns5010005. View